Ersodetug Shows Hypoglycemia Reduction Trends, Target Engagement in Phase 3 cHI Trial
Huseyin Demirbilek, MD
Advertisement
Hüseyin Demirbilek is a pediatric endocrinologist at Hacettepe University Faculty of Medicine in Ankara, Turkey.
Articles by Huseyin Demirbilek, MD
Ersodetug showed target engagement and hypoglycemia reduction trends in phase 3 cHI study but missed primary endpoints in SunRIZE trial.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
One Year Later: How Brensocatib Has Changed Bronchiectasis Care
2
FCS Diagnosis and Management Explained: Clinical Forum Insights
3
Germline Variants May Predict CAR T Cell Toxicity, With Mark Leick, MD
4
Q&A: PORT-77 Phase 2a Results in Adults with EPP and XLP
5